Hormone replacement therapy and cognitive performance: The role of homocysteine

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 58, Issue 4, 2003, Pages 324-330

  Whitmer, Rachel A ^a,e   Haan, Mary N ^b   Miller, Joshua W ^c   Yaffe, Kristine ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LIPID;

ACADEMIC ACHIEVEMENT; ADULT; AGE DISTRIBUTION; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COGNITION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FOLIC ACID BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYSTERECTOMY; INCOME; LIPID BLOOD LEVEL; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; MULTIPLE REGRESSION; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; VITAMIN BLOOD LEVEL; WORD RECOGNITION;

EID: 0037380339     PISSN: 10795006     EISSN: None     Source Type: Journal    
DOI: 10.1093/gerona/58.4.m324     Document Type: Article

References (40)

1. Goldstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement therapy in postmenopausal women. Prognos Cardiovasc Dis. 1996;38:199-210.
2. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992;117:1016-1037.
3. Hulley S, Grady D, Bush T, et al., for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
4. Writing Group for the Women's Health Initiative Investigators. JAMA. 2002;288:321-323.
5. Barrett-Connor E, Kritz-Silverstein D. Estrogen replacement therapy and cognitive function in older women. JAMA. 1993;269:2673-2641.
6. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory. A possible protective effect? Neurology. 1997;49:1491-1497.
7. Yaffe K, Haan M, Byers A, Tangen C, Kuller L. Estrogen use, APOE, and cognitive decline: evidence of gene-environment interaction. Neurology. 2000;54:1949-1954.
8. Carlson MC, Zandi PP, Plassman BL, et al. Hormone replacement therapy and reduced cognitive decline in older women. Neurology. 2001;57:2210-2215.
9. Hogervorst E, Williams J, Budge M, Riedel W, Jolles J. The nature of the effect of female gonadal hormone replacement therapy on cognitive function in post-menopausal women: a meta-analysis. Neuroscience. 2000;101:485-512.
10. Asthana S, Baker LD, Craft S, et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 2001;57:605-612.
11. Mulnard RA, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283:1007-1015.
12. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061-2066.
13. Legault C, Stefanick ML, Miller V, Marcovina S, Schrott H. Effect of hormone replacement therapy on the validity of the Friedwald equation in postmenopausal women: the PEPI Trial. J Clin Epidemiol. 1999;52:1187-1195.
14. Lip G, Blann A, Jones A, Beevers G. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. Circulation. 1997;134:764-771.
15. Shlipak M, Simon J, Vittinghoff E, et al. Estrogen and progestin, lipoprotein(a) and the risk of recurrent coronary heart disease events after menopause. JAMA. 2000;283:1845-1852.
16. Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Intervention Trial. J Women's Health Gender Based Med. 1999;9:1167-1172.
17. Mijatovic V, Netelenbos C, van der Mooren MJ, de Valk-Roo GW, Jakobs C, Kenemans P. Randomized, double-blind, placebo controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril. 1998;70:1085-1089.
18. van der Mooren MJ, Wouters MG, Blom HJ, Schellekens LA, Eskes TK, Rolland R. Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur J Clin Invest. 1994;24:733-736.
19. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. The effects of hormone replacement therapy and raloxifene on c-reactive protein and homocysteine in healthy postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab. 2000;85:214-218.
20. Yildirir A, Aybar F, Tokogozoglu L, et al. Effects of hormone replacement therapy on plasma homocysteine and C-reactive protein levels. Gynecol Obstet Invest. 2002;43:54-58.
21. Aronow WS, Ahn C, Gutstein H. Increased plasma homocysteine is an independent predictor of new atherothromobotic brain infarction in older persons. Am J Cardiol. 2000;86:585-586, A10.
22. Bostom AG, Rosenberg IH, Silbershatz H, et al. Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: the Framingham Study. Ann Intern Med. 1999;13:352-355.
23. Kitner SJ, Giles WH, Macko RF, et al. Homocysteine and risk of cerebral infarction in a biracial population: the stroke prevention in young women study. Stroke. 1999;20:1554-1560.
24. Clark R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12 and serum total homocysteine levels in combined Alzheimer's disease. Arch Neurol. 1998;55:1449-1455.
25. Nilsson K, Gustafson L, Faldt R, Andersson A, Brattstrom L, Lindgren A, et al. Hyperhomocysteinemia - a common finding in a psychogeriatric population. Eur J Clin Invest. 1996;26:853-859.
26. Budge M, Johnston C, Hogervorst E, et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann NY Acad Sci. 2000;903:407-410.
27. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dementia Geriatr Cogn Disord. 1999;10:12-20.
28. McCaddon A, Davies G, Hudson P, et al. Total serum homocysteine in senile dementia of the Alzheimer's type. Int J Geriatr Psychiatr. 1998;13:235-2239.
29. Riggs KM, Spiro A, Tucker K, Rush D. Relations of vitamin B12, vitamin b-6, folate, and homocysteine to cognitive performance in the Normative Aging Study. Am J Clin Nutr. 1996;63:306-314.
30. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
31. Haan MN, Mungas DM, Gonzalez HM, Jagust WJ, Ortiz TO. Prevalence of dementia in older Mexican Americans: the influence of type 2 diabetes, stroke, and genetic factors. J Am Geriatr Soc. In press.
32. Cuellar I, Arnold B, Maldonado R. Acculturation Rating Scale for Mexican-Americans-II: a revision of the original ARSMA Scale. Hispanic J Behav Sci. 1995;17.
33. Gilfix BM, Blank DW, Rosenblatt DS. Novel reductant for determination of total plasma homocysteine. Clin Chem. 1997;43:687-688.
34. Teng EL, Chui HC. The Modified Minimental State Examination. J Clin Psychiatr. 1987;48:314-318.
35. Mungas D, Reed BR, Marshall SC, Gonzalez HM. Development of psychometrically matched English and Spanish language neurophysiological tests for older persons. Neuropsychology. 2000;14:209-223.
36. SAS, Version 6.12. Cary, NC: SAS Institute; 1996.
37. Althausen S, Paschen W. Homocysteine-induced changes in mRNA levels of genes coding for cytoplasmic and endoplasmic reticulum-resident stress proteins in neuronal cell cultures. Brain Res Mol Brain Res. 2000;84:32-40.
38. Kruman IL, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitoxicity. J Neurosci. 2000;20:6920-6926.
39. White AR, Huang X, Jobling MF, et al. Homocysteine potentiates copper and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem. 2001;76:1509-1520.
40. Ho PI, Collins SC, Dhitavat S, et al. Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem. 2001;78:249-253.